Table 2.
Association between, on one hand, in vitro granulocyte responses, PBMC responses and baseline antibody levels and, on the other, baseline inflammatory markers, Larsen score and changes in Larsen score during the first 2 years after RA diagnosis
| Baseline CRP | Baseline ESR | Baseline Larsen score | 1-year Larsen score | 2-year Larsen score | ∆ Larsen score 1 – 0 years | ∆ Larsen score 2 – 0 years | ∆ Larsen score 2 – 1 years | |
|---|---|---|---|---|---|---|---|---|
| CD16 (PMN) | 35/16.5 (0.08) | 35.5/19.5 (0.26) | 14.4/5.5 (0.024) | 22.5/11.0 (0.034) | 24.0/31.1 (0.046) | 7.3/3.0 (0.08) | 9.0/6.3 (0.88) | 3.0/2.3 (0.27) |
| CD66b (PMN) | 49/14 (0.004) | 33/19 (0.063) | 13.5/6.0 (0.15) | 22.0/11.0 (0.071) | 24.0/13.2 (0.059) | 7.5/2.6 (0.017) | 10.4/5.2 (0.016) | 5.1/2.3 (0.012) |
| MPO (PMN) | 14/18 (0.6) | 19/21 (0.61) | 5.4/7.0 (0.69) | 17.0/11.0 (0.99) | 17.7/13.2 (0.97) | 6.9/2.8 (0.27) | 9.6/5.3 (0.41) | 2.5/2.3 (0.37) |
| ΤΝFα (PBMC) | 28/17 (0.18) | 43/19 (0.049) | 9.3/6.3 (0.57) | 11.6/11.8 (0.75) | 15.3/13.2 (0.52) | 5.6/3.0 (0.50) | 9.4/5.3 (0.43) | 2.9/2.3 (0.48) |
| Anti-CII | 36.5/14 (0.012) | 29/19 (0.10) | 11.5/6.3 (0.75) | 16.0/11.0 (0.44) | 15.0/13.5 (0.44) | 4.3/3.6 (0.21) | 8.1/5.3 (0.22) | 2.6/2.3 (0.29) |
| Anti-CCP | 15/18.5 (0.20) | 23/20 (0.57) | 6.8/7.0 (0.76) | 13.0/10.5 (0.76) | 15.8/12.0 (0.42) | 4.6/2.5 (0.41) | 8.3/5.3 (0.12) | 3.0/1.5 (0.024) |
| RF | 15/18 (0.65) | 23/20 (0.66) | 6.0/7.9 (0.17) | 11.0/12.0 (0.52) | 14.0/13.5 (0.64) | 4.4/3.6 (0.71) | 6.3/7.0 (0.44) | 3.0/1.8 (0.049) |
Data presented as median level for patients with significant change/not significant change in the parameter shown in the left column. Statistics were performed with the Mann–Whitney U test. P values are shown within parentheses; significant values are in bold. anti-CII, collagen type II autoantibodies; anti-CCP, cyclic citrullinated peptide antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MPO, myeloperoxidase; PBMC, peripheral blood mononuclear cells; PMN, polymorphonuclear granulocytes; RA, rheumatoid arthritis; RF, rheumatoid factor; TNFα, tumor necrosis factor alpha.